JNM Maintains Strong Metrics in 2023 Journal Citation Reports
Reston, VA—The
Journal of Nuclear Medicine (JNM)—the flagship publication of
the Society of Nuclear Medicine and Molecular Imaging—has maintained its status
as one of the top medical imaging journals worldwide, according to new data
just released in Clarivate's 2023 Journal Citation Reports. With an impact
factor of 9.1, JNM saw increases in its five-year impact factor, journal
citation indicator, and article influence score, among other categories.
“This is an exciting time for nuclear medicine, with ground-breaking advances
in molecular imaging, theranostics, artificial intelligence, and other areas,”
said Johannes Czernin, MD, JNM editor-in-chief and professor of
molecular and medical pharmacology and chief of the Ahmanson Translational
Theranostics Division at the UCLA David Geffen School of Medicine, Los Angeles,
California.
Of 204 medical imaging journals included in the Clarivate report, JNM ranked sixth overall. JNM’s journal citation indicator (JCI) achieved
its highest rating to date, jumping from 2.59 to 2.98 percent. The
JCI is a single score given to each journal based on normalized citations across
three full years of citation data. As average performance is set to 1.0, JNM’s
JCI rating of 2.98 percent means the journal performed close to three times
better than average. In addition, the journal’s five-year impact factor increased from
9.0 to 9.1, and the article influence score rose from 2.257 to 2.606. The normalized
Eigenfactor score also increased from 5.7023 to 6.11.
“The JNM editorial team is very
intentional in the articles that it chooses for publication in the journal,”
notes Czernin. “By keeping our pulse on advances in the field and adhering to
rigorous quality standards, we strive to make the journal an invaluable
resource for the nuclear medicine and molecular imaging field. I applaud the entire
team, from the associate editors and reviewers to SNMMI Publications Committee
to journal staff for their contributions to JNM.”
Visit the JNM website for the latest research,
and follow our new Twitter and Facebook pages @JournalofNucMed
or follow us on LinkedIn.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with
the researchers, please contact Rebecca Maxey at (703) 652-6772 or [email protected].
# # #
About JNM and the Society of
Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine
(JNM) is the world’s leading nuclear medicine, molecular imaging and
theranostics journal, accessed more than 16 million times each year by
practitioners around the globe, providing them with the information they need
to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online
at http://jnm.snmjournals.org.
JNM is published by the Society
of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific
and medical organization dedicated to advancing nuclear medicine and molecular
imaging—precision medicine that allows diagnosis and treatment to be tailored
to individual patients in order to achieve the best possible outcomes. For more
information, visit www.snmmi.org.